Mepolizumab Reduces Remissions in EGPA Patients

MAY 23, 2017
Thomas Castles
Mepolizumab helped patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare condition that causes vasculitis in people with a history of airway allergic hypersensitivity, experience significantly more weeks in remission than those that took placebo, according to Michael E Wechsler, MD, MMSc, professor of medicine and director of the asthma program at National Jewish Health, Denver, Colorado.

In a phase III study supported by grants from GlaxoSmithKline and the National Institutes of Health, among others, mepolizumab met all primary and secondary outcomes, Wechsler said during a presentation at the 2017 American Thoracic Society conference in Washington, DC.

Primary outcomes were accrued weeks of remission out to 52 weeks, and the proportion of patients who achieved remission at weeks 36 and 48. Secondary outcomes included the time to first relapse and the average daily glucocorticoid dose.

The study began with the random assignment of participants with relapsing or refractory EGPA who had received treatment for at least 4 weeks and were taking stable corticosteroids to receive mepolizumab or placebo. In the mepolizumab-treated group, 300mg of mepolizumab was administered subcutaneously every month for one year, even though current approved dosing for asthma is only 100mg per month.

“There was a significantly greater proportion of patients in the study’s mepolizumab-treated arm who ended up achieving remission in terms of the number of weeks but also in terms of the proportion of patients who were in remission at weeks 36 and 48,” Wechsler said.

Another important outcome, he added, was the rate of exacerbations or relapses.

“Mepolizumab-treated patients ended up having a 50% reduction in the frequency of EGPA exacerbations that often consisted of worsening asthma, worsening sinus disease or vasculitis that ended up requiring either escalation in dosing or corticosteroids, additional therapies, hospitalization or urgent care visits,” he said.

The drug also resulted in a significant reduction in corticosteroid dosing – an endpoint that patients are particularly interested in, Wechsler emphasized.

“The mean dose of prednisone that patients were on at the beginning of the study was 11 to 12mg per day. Patients treated with mepolizumab ended up having an over 50% reduction in corticosteroid dosing, and a large proportion were able to get down to less than 4g per day,” he said. “In fact, while only 3% of patients were able to come off of corticosteroids in the placebo arm, almost 20% of patients in the mepolizumab-treated arm were able to come off corticosteroids completely.”

Mepolizumab-treated patients also experienced significant improvements in lung function, asthma control questionnaire scores, nasal testing scores and other outcomes.

“If you consider relapse-free time, a 50% reduction in corticosteroid dosing, as well as the proportion of patients who were able to achieve remission, almost 80% of patients treated with mepolizumab ended up achieving success with that therapy,” Wechsler explained.

The study’s results suggest that EGPA needs to be better recognized in general practice, he said. It can be identified when high levels of blood eosinophils are found.

The first step is to recognize EGPA, and the second thing is to try to identify patients who may not respond to standard of care therapy,” Wechsler said. “All in all, we view this study as a significant success and a significant benefit for patients with EGPA, and hope that it will lead to better outcomes in the future for these patients.” 


Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.